Leptin-R and Its Association with PI3K/AKT Signaling Pathway in Papillary Thyroid Carcinoma
Overview
Oncology
Authors
Affiliations
The putative role of leptin and its receptor (Ob-R) in the pathogenesis of various primary human malignancies has been reported; however, their role in papillary thyroid cancer (PTC) has not yet been evaluated. We investigated the role of Ob-R in a large tissue microarray cohort of PTC followed by in vitro studies using a panel of PTC cell lines. Ob-R overexpression was seen in 80% PTCs and was significantly associated with poor disease-free survival (P=0.0235). PTCs that overexpressed Ob-R showed a aggressive phenotype characterized by older age, extrathyroid extension, larger tumor size, nodal metastasis, advanced stage, tall cell variant histological subtype, and a poor disease-free survival (P=0.0005, P=0.0006, P=0.0398, P=0.0004, P=0.0111, P=0.0003, and P=0.0235 respectively). However, Ob-R expression was not an independent prognostic marker to predict disease-free survival in multivariate analysis. PTCs with overexpression of Ob-R showed a significant direct association with overexpression of XIAP (P<0.0001) and Bcl-XL (P<0.0001). In vitro analysis showed that leptin stimulated cell proliferation and inhibited apoptosis via activation of phosphatidylinisitol 3' kinase (PI3K)/protein kinase B (AKT) signaling pathway. Inhibition of PI3K activity by its inhibitor LY294002 abrogated leptin-mediated PI3K/AKT signaling. Gene silencing of Ob-R in PTC cells resulted in downregulation of phospho-AKT, Bcl-XL, and XIAP expression suggesting that leptin-mediated pathogenesis of PTC occurs via involvement of these downstream targets. Altogether, these data show that leptin plays an important role in PTC pathogenesis through PI3K/AKT pathway via Ob-R and is a potential prognostic marker associated with an aggressive phenotype and poor disease-free survival.
The role of neck adipose tissue in lymph node metastasis of head and neck cancer.
Pan Y, Xu Y, Fan C, Miao X, Shen Y, Wang Q Front Oncol. 2024; 14:1390824.
PMID: 38800384 PMC: 11116645. DOI: 10.3389/fonc.2024.1390824.
Characterization of Thyroid Cancer among Hispanics in California, USA, from 2010 to 2020.
Hsu R, Tsai K, Benjamin D, Chennapan K, Wojcik K, Lee A Cancers (Basel). 2024; 16(6).
PMID: 38539437 PMC: 10969047. DOI: 10.3390/cancers16061101.
Association of High Serum Leptin Level with Papillary Thyroid Carcinoma: A Case-Control Study.
Refahi R, Heidari Z, Mashhadi M Int J Hematol Oncol Stem Cell Res. 2023; 17(3):210-219.
PMID: 37817973 PMC: 10560642. DOI: 10.18502/ijhoscr.v17i3.13311.
Sweis N, Zayed A, Al Jaberi M, Alqirem L, Hyasat T, Khraisat F Endocrine. 2023; 81(3):432-449.
PMID: 37129757 DOI: 10.1007/s12020-023-03378-8.
Metabolic syndrome and thyroid Cancer: risk, prognosis, and mechanism.
Li L, Song J, Liu H, Chen C Discov Oncol. 2023; 14(1):23.
PMID: 36811728 PMC: 9947216. DOI: 10.1007/s12672-022-00599-7.